Derivative exercise or conversion — not an open-market buy.
Traded Nov 11, 2025 · Filed Nov 13, 2025
Steris's Sr. VP, Gen Counsel, and Sec. sold $3.98M of Steris shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$3,977,100
Shares × reported transaction price
6 days after results of Nov 5, 2025, 85 days before results of Feb 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $266.70 on Nov 11, 2025, at its 52-week high, after an 8% rise over the previous 30 trading days
52-week range $202.46 (Jan 2, 2025) to $266.70 (Nov 11, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $247.44 on Sep 30, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +1.9% | -1.9% | +3.8% |
| 30 days | -1.7% | +1.3% | -3.0% |
| 90 days | -5.5% | +1.4% | -6.9% |
| 180 days | -18.3% | +10.5% | -28.8% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
14K → 11K shares held−21% of their stake
Steris's Sr. VP and GM, Life Sciences sold $752K of Steris shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.